Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C(44)Mab-3 for Multiple Applications against Pancreatic Carcinomas

Pancreatic cancer exhibits a poor prognosis due to the lack of early diagnostic biomarkers and the resistance to conventional chemotherapy. CD44 has been known as a cancer stem cell marker and plays tumor promotion and drug resistance roles in various cancers. In particular, the splicing variants ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Yuma, Suzuki, Hiroyuki, Tanaka, Tomohiro, Kaneko, Mika K., Kato, Yukinari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204397/
https://www.ncbi.nlm.nih.gov/pubmed/37218897
http://dx.doi.org/10.3390/antib12020031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204397/
https://www.ncbi.nlm.nih.gov/pubmed/37218897
http://dx.doi.org/10.3390/antib12020031

Ejemplares similares